Business Identifier: NO Business Identifier is currently available for this company.
Public Profile: Biotechnology company X-in8 Biologicals Corp., a spinoff from the laboratories at the University of North Carolina at Chapel Hill. X-in8 is developing therapies that can fight inflammation and other tissue damage as blood flow is restored after the blood supply has been restricted for a period of time, such as after an organ transplant. The damage that can occur is called ischemia-reperfusion injury, or IRI. Prncipals of the firm are working on a way to keep naturally occurring proteins from contributing to IRI. Egan said the compounds he is developing could reduce tissue damage after transplants. The technology could also be developed for heart surgery as well as heart attack and stroke applications.